Please assess the completion status of the following clinical trial:

Trial Title: Opioid Growth Factor (OGF) and Gemcitabine: Novel Treatment for Pancreatic Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* unresectable and histological or cytological confirmation of adenocarcinoma of the pancreas and measurable disease by CT scan~* patient has not been previously treated for pancreatic cancer~Exclusion Criteria:~* history of cancer other than pancreatic cancer (excluding resected basal cell skin cancer or curative stage 1 cervical cancer if disease free for 5 years or more)~* previous treatment with chemotherapy for pancreatic cancer~* uncontrolled cardiovascular disease (congestive heart failure, symptoms of coronary artery disease, cardiac arrhythmias)~* suffered from myocardial infarction in preceding 6 months~* poorly controlled medical conditions including: asthma, chronic obstructive pulmonary disease, diabetes, seizure disorders, known brain metastases, hepatic or renal failure~* pregnant or nursing women~* known allergy to gemcitabine

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- OGF & Gemcitabine (Type: EXPERIMENTAL): Opioid Growth factor 250 ug/kg IV once a week. Gemcitabine 1000 mg/m2 weekly for 7 out of 8 weeks induction then every 3 out of 4 week cycles.

Based on this trial design, predict the completion outcome and termination type (if applicable).